The Food and Drug Administration's about-face comes a little more than a week after the agency refused to consider the company's application to market the new kind of influenza vaccine.

Tempus AI, Inc. (NASDAQ:TEM) shares are climbing today after the company unveiled a new AI-powered cancer diagnostic algorithm, building momentum ahead of its Q4 2025 earnings report scheduled for ...

A potential massive breakthrough!

Moderna held further discussions with regulators and announced that the agency would accept the company’s application for approval of its flu vaccine that uses mRNA technology.

The brain's ability to do everything from forming memories to coordinating movement relies on its cells producing the right proteins at the right time. But directly measuring this protein production, ...

Thermo Fisher Scientific has introduced a laboratory kit designed to extract protein, DNA and RNA from a single biological ...

A research team at the University of Würzburg has deciphered another aspect of poxviral gene activation. They have revealed a ...

Tempus HRD-RNA is an AI-driven, 1,660-gene logistic regression model designed to identify patients likely to respond to ...

Release summary: Molecular Instruments launches fully ambient-temperature HCR (TM) Pro RNA-ISH on the BOND-III, marking a new generation of clinical-grade RNA-ISH designed to reduce heat-driven ...

The Oligonucleotide Cdmo Market plays a critical role in supporting modern industries by providing scalable, compliant, and cost-effective manufacturing solutions. It ensures the timely supply of ...

BioVenic is dedicated to advancing the advancement of veterinary molecular diagnostics through its comprehensive ...

Two separate laboratory breakthroughs have produced RNA molecules that can build copies of themselves or assemble functional ...